Clindamycin: an evaluation of its role in dental patients.
A review of the etiology of orofacial infections, of the pharmacology and spectrum of clindamycin and its associated complications, and a treatment plan for orofacial infections have been presented. On the basis of the data presented, it would seem that except for proved B fragilis infections, clindamycin is not a first-line drug for infections of the orofacial region. There are, however, indications for its use that have been presented. The serious complications associated with its use have also been presented. A high index of suspicion must be maintained regarding the development of these complications if clindaymcin is to be used.
D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D001439:Bacteroides / Q000187:drug effects; D001442:Bacteroides Infections / Q000188:drug therapy / Q000382:microbiology; D002981:Clindamycin / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D003875:Drug Eruptions / Q000209:etiology; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced; D005145:Face / Q000382:microbiology; D006801:Humans; D009055:Mouth / Q000382:microbiology; D009059:Mouth Diseases / Q000188:drug therapy / Q000382:microbiology
D002981:Clindamycin